| Literature DB >> 26919427 |
Benjamin A Olenchock1, Javid Moslehi2, Alan H Baik3, Shawn M Davidson4, Jeremy Williams5, William J Gibson6, Abhishek A Chakraborty, Kerry A Pierce7, Christine M Miller8, Eric A Hanse9, Ameeta Kelekar9, Lucas B Sullivan4, Amy J Wagers8, Clary B Clish7, Matthew G Vander Heiden10, William G Kaelin11.
Abstract
Ischemic preconditioning is the phenomenon whereby brief periods of sublethal ischemia protect against a subsequent, more prolonged, ischemic insult. In remote ischemic preconditioning (RIPC), ischemia to one organ protects others organs at a distance. We created mouse models to ask if inhibition of the alpha-ketoglutarate (αKG)-dependent dioxygenase Egln1, which senses oxygen and regulates the hypoxia-inducible factor (HIF) transcription factor, could suffice to mediate local and remote ischemic preconditioning. Using somatic gene deletion and a pharmacological inhibitor, we found that inhibiting Egln1 systemically or in skeletal muscles protects mice against myocardial ischemia-reperfusion (I/R) injury. Parabiosis experiments confirmed that RIPC in this latter model was mediated by a secreted factor. Egln1 loss causes accumulation of circulating αKG, which drives hepatic production and secretion of kynurenic acid (KYNA) that is necessary and sufficient to mediate cardiac ischemic protection in this setting.Entities:
Mesh：
Substances：
Year: 2016 PMID： 26919427 PMCID： PMC4819986 DOI： 10.1016/j.cell.2016.02.006
Source DB: PubMed Journal: Cell ISSN： 0092-8674 Impact factor: 41.582